- Home
- MFIN vs PRQR Comparison
MFIN vs PRQR Comparison
Compare MFIN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | PRQR |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | Netherlands |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 262.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MFIN | PRQR |
|---|---|---|
| Price | $11.95 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $7.25 |
| AVG Volume (30 Days) | 51.9K | ★ 704.3K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | $13.92 |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.33 |
| 52 Week High | $12.26 | $3.10 |
Technical Indicators
Market Signals| Indicator | MFIN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 40.43 |
| Support Level | $11.40 | $1.37 |
| Resistance Level | $12.26 | $1.99 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 71.10 | 16.35 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.